Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has experienced a significant positive shift following the announcement of Medicare coverage for its proprietary NeXT Personal MRD test, leading to a notable 28% increase in stock value, which reflects strong market confidence in its offerings. The company's strategic decision to ease volume growth in Q3 to manage cash burn while awaiting reimbursement indicates a prudent financial approach that prioritizes long-term profitability. Additionally, expectations of accelerated marketing efforts by its commercial partner Tempus, combined with promising sales forecasts for its product line, support a bullish outlook on the company's future financial performance and market positioning.

Bears say

Personalis Inc. has faced challenges in meeting its revenue expectations due to a general slowdown in the biopharma industry and logistical issues affecting sample flow for minimal residual disease (MRD) testing, leading to a downward revision of its 2025 revenue guidance from $70-$80 million to $68-$73 million. The company's projected decline in revenue from biopharma services, specifically a $3 million reduction at the midpoint, coupled with significant losses incurred since inception and existing debt, raises concerns about its ability to achieve profitability in the near future. Additionally, the expected decrease in reimbursement for clinical sample testing further exacerbates the risks surrounding Personalis's financial outlook.

Personalis Inc (PSNL) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.